Proxy Governance and Egan-Jones Recommend Renovis Shareholders Vote For Merger With Evotec
April 25 2008 - 3:30PM
PR Newswire (US)
SOUTH SAN FRANCISCO, Calif., April 25 /PRNewswire-FirstCall/ --
Renovis, Inc. (NASDAQ:RNVS), today announced that PROXY Governance,
Inc. and Egan-Jones Proxy Services have joined ISS/Risk Metrics and
Glass Lewis & Co. in recommending that Renovis stockholders
vote "FOR" the merger agreement with Evotec AG (Frankfurt Stock
Exchange: EVT) at the Special Meeting of Stockholders scheduled for
May 1, 2008. In the proposed merger, each share of Renovis common
stock will be converted into the right to receive American
Depositary Share (ADSs) of Evotec representing 1.0542 Evotec
ordinary shares. With these recommendations, all four leading
independent proxy advisory firms have recommended that Renovis
stockholders support the transaction with Evotec. The Board of
Directors of Renovis unanimously recommends that stockholders vote
"FOR" the approval and adoption of the agreement and plan of
merger, and the approval of the merger and related transactions as
described in the proxy statement/prospectus. The company encourages
all stockholders to vote their shares promptly by phone, Internet,
or by mailing their proxy card, and to contact MacKenzie Partners
at 800/322-2885 or collect at 212/929-5500 if they have any
questions or need any assistance in voting their shares. About
Renovis Renovis is a biopharmaceutical company focused on the
discovery and development of drugs for major medical needs in the
areas of neurological and inflammatory diseases. The Company's
proprietary research programs focus on the purinergic receptors,
P2X3 and P2X7, for the potential treatment of pain and inflammatory
diseases. In addition, Renovis has a worldwide collaboration and
license agreement with Pfizer to research, develop and
commercialize small molecule vanilloid receptor (VR1). For
additional information about the company, please visit
http://www.renovis.com/. Forward-Looking Statements This
communication contains certain forward-looking statements. All
statements, other than statements of historical facts, regarding
the likelihood and timing of the completion of the business
combination transaction involving Evotec and Renovis, the
conversion of Renovis shares into a right to receive Evotec shares,
the anticipated benefits of such transaction and the plans and
objectives of management are forward-looking statements and are
based on management's current expectations and estimates. We may
not actually achieve these plans, intentions or expectations and
Renovis cautions investors not to place undue reliance on our
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
the forward-looking statements we make. Factors that could cause or
contribute to such differences may include, but are not limited to,
risks relating to the integration of the technologies and
businesses of Evotec and Renovis, unanticipated expenditures,
changing relationships with customers, suppliers and strategic
partners, conditions of the economy and other factors described in
the Registration Statement on Form F-4 filed with the SEC by Evotec
and the most recent reports on Form 10-K, Form 10-Q, Form 8-K and
other periodic reports filed by Renovis with the SEC. Additional
information about the transaction Renovis filed a Current Report on
Form 8-K with the Securities and Exchange Commission on September
24, 2007, that includes as an exhibit the Agreement and Plan of
Merger between Evotec and Renovis. Evotec and Renovis have mailed a
joint proxy statement/prospectus to stockholders of Renovis in
connection with the proposed merger. This document contains
important information about the merger and should be read before
any decision is made with respect to the merger. Investors and
stockholders will be able to obtain free copies of this document
and any other documents filed or furnished by Evotec or Renovis
through the website maintained by the Securities and Exchange
Commission at http://www.sec.gov/. Free copies of these documents
may also be obtained from Renovis by directing a request to
Renovis' Investor Relations department at Two Corporate Drive,
South San Francisco, California 94080 or from Evotec by directing a
request to Evotec's Investor Relations department at
Schnackenburgallee 114, 22525 Hamburg, Germany. In addition to the
documents referenced above, Renovis files or furnishes annual,
quarterly and current reports, proxy statements and other
information with the Securities and Exchange Commission. You may
read and copy any reports, statements or other information filed or
furnished by Renovis at the SEC's Public Reference Room at Station
Place, 100 F Street, N.E., Washington, D.C. 20549. You can request
copies of these documents by writing to the SEC and paying a fee
for the copying cost. Please call the SEC at 1-800-SEC-0330 for
more information about the operation of the Public Reference Room.
Renovis's SEC filings are also available to the public at the SEC's
web site at http://www.sec.gov/, or at http://www.renovis.com/.
DATASOURCE: Renovis, Inc. CONTACT: Shari Annes of Renovis, Inc.,
+1-650-888-0902, Web site: http://www.renovis.com/
Copyright
Renovis (MM) (NASDAQ:RNVS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Renovis (MM) (NASDAQ:RNVS)
Historical Stock Chart
From Oct 2023 to Oct 2024